p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Narra J
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Fungistatic activity and mechanism of Caulerpa racemosa, Caulerpa lentillifera fractions and caulerpin metabolite against pathogenic fungi Nursidika, Perdina; Julianti, Elin; Kurniati, Neng F.
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.1714

Abstract

The increasing prevalence of azole resistance in various fungal species presents a significant concern, highlighting the urgent need for new antifungal agents. The aim of this study was to investigate the antifungal activity of fractions from Caulerpa racemosa, C. lentillifera, and caulerpin against three species: Aspergillus flavus, A. niger, and Candida albicans. The Caulerpa extracts were obtained through maceration with 96% ethanol, followed by fractionation using vacuum liquid chromatography. Antifungal activity was assessed using the broth microdilution method, while fungal growth kinetics were evaluated through time-kill curves. Bioautography was employed to identify inhibitory compounds, while liquid chromatography high-resolution mass spectrometry (LC-HRMS) was utilized to detect the contents of the extracts and fractions. Scanning electron microscopy (SEM) was used to observe the fungal structure, and the absorbance at 260/280 nm was measured to evaluate the cell leakage. LC-HRMS identified numerous compounds in C. racemosa and C. lentillifera with antifungal activities, including fatty acids, terpenes, alkaloids, flavonoids, and coumarins. The results indicate that the fractions of both Caulerpa did not inhibit the growth of A. flavus and A. niger, but effectively inhibited C. albicans. Among the fractions, F3CR and F4CL exhibited the highest antifungal efficacy against C. albicans, with minimum inhibitory concentrations (MICs) ranging from 64 to 128 µg/mL. Caulerpin, the primary metabolite of Caulerpa, also demonstrated significant inhibition, with an MIC of 256 µg/mL. The findings suggested that F3CR, F4CL, and caulerpin possessed fungistatic properties. Bioautography results revealed clear zones in the colonies, indicating inhibited fungal growth. The SEM observations showed that fungal cells became rough, perforated, and damaged, which was confirmed by the increase in absorbance at 260/280 nm, suggesting the release of cellular components such as nucleotides and proteins. In conclusion, both Caulerpa species and caulerpin are promising candidates for developing new antifungal agents against C. albicans.
Design of lipid nanoparticle (LNP) containing genetic material CRISPR/Cas9 for familial hypercholesterolemia Prasetia, I GNJA.; Kurniati, Neng F.; Riani, Catur; Mudhakir, Diky
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.2217

Abstract

Familial hypercholesterolemia is a genetic disorder caused by mutations in the low-density lipoprotein receptor gene (LDLR) and the current treatment still focuses on symptom management. The aim of this study was to develop a lipid nanoparticle (LNP)-based delivery system for the CRISPR/Cas9 component in correcting LDLR gene mutations. LNPs were prepared using an ultrasonic-solvent emulsification technique by varying the surfactant: oil ratio (SOR), homogenization speed and time, and sonication time. Next, the LNP surface was modified by adding DSPE-PEG2000-NH2 and polyethyleneimine. The next stage is to design the single guide RNA (sgRNA) and Donor DNA wildtype (Donor DNA wt). This genetic material was complexed with LNP and then transfected into Hepa1-6 LDLR mt cells, an in vitro representation of cells suffering from familial hypercholesterolemia. This optimization process produced LNPs with a particle size of 118.6±0.8 nm and a polydispersity index of 0.34±0.03. The LNP surface modification resulted in a zeta potential of +7.5 mV. A transmission electron microscope (TEM) analysis howed spherical morphology with size distribution following a regular pattern. LNP cell viability tests showed good biocompatibility at concentrations <15 mM with a half-maximal inhibitory concentration (IC50) value of 27.7 mM. The dominant cellular uptake mechanism of LNP was through the clathrin-mediated endocytosis (CME) pathway. The Hepa1-6 LDLR mt cell model was successfully produced with the transfecting agent Lipofectamine 3000 by homology-directed repair (HDR) mechanism. The LNP-genetic material complex with a ratio of sgRNA:Cas9:Donor DNA wt (1:1:0.04) showed an increase in LDLR gene expression of 3.3±0.2 times and LDLR protein levels reached 12.95±0.25 ng/mL on day 4 after transfection. The results of this study indicate that the developed LNP-based delivery system has the potential for gene therapy applications in familial hypercholesterolemia.